Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: US approval for Lilly’s Alzheimer's contender; the challenges and rewards of late-stage ADCs; Eisai regains control of ADC from BMS; RSV vaccine developers hit by declining expectations; and an interview with Amgen’s Ian Thompson.

Scrip Five Must Know Things
weekly audio roundup of selected content from Scrip's global team

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 5 July 2024, including: US approval for Eli Lilly and Company’s Alzheimer's contender; the challenges and rewards of late-stage ADCs; Eisai Co., Ltd. regains control of ADC from Bristol Myers Squibb Company; RSV vaccine developers hit by declining expectations; and an interview with Amgen, Inc.’s Ian Thompson.

This and all our other podcasts are available on the Citeline channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "Lilly’s Kisunla Set To Give Leqembi A Run For Its Money In Early Alzheimer’s" - Scrip, 3 July, 2024.)

(Also see "Big Pharma Leads Development Of Novel Antibody-Drug Conjugates" - Scrip, 28 June, 2024.)

(Also see "Eisai Regains Full Control Of ADC Program After Bristol R&D Reprioritization" - Scrip, 1 July, 2024.)

(Also see "Moderna And GSK Hit By Declining RSV Vaccines Expectations" - Scrip, 28 June, 2024.)

(Also see "Amgen’s Ian Thompson On Payer Shifts, Obesity Opportunity And The Future Of Blockbusters" - Scrip, 28 June, 2024.)

Citeline · Scrip's Five Must-Know Things - 8 July 2024

Open Media

More from New Products

Gilead’s Yeytuo, Lilly’s Kisunla Headline CHMP Positive Opinions

 

Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Pipeline Watch: Five Approvals And Twelve Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Executives On The Move: Three New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.